Overview

Treatment of Upper Extremity Deep-Vein Thrombosis

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Oklahoma
Collaborator:
Pfizer
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin
Warfarin
Criteria
Inclusion Criteria:

- Patients with confirmed upper extremity DVT diagnosed by ultrasound imaging or
venogram

Exclusion Criteria:

- Active, clinically significant bleeding

- Known hypersensitivity to heparin or low-molecular weight heparin

- Currently pregnant or less than 1 week post-partum

- Acquired bleeding diathesis

- Known inherited bleeding disorder

- Renal failure

- Extremes of weight

- Poor performance status

- Unable to return for repeat diagnostic testing or follow-up visits